UK markets closed

Orphazyme A/S (ORPHA.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
1.6050-0.0970 (-5.70%)
At close: 04:59PM CEST
Full screen
Previous close1.7020
Open1.6340
Bid1.5310 x 0
Ask1.5510 x 0
Day's range1.2310 - 1.6990
52-week range1.1000 - 109.1000
Volume319,211
Avg. volume275,896
Market cap56.676M
Beta (5Y monthly)1.07
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Restructuring Proposal

    Orphazyme A/S in restructuringCompany announcementNo. 26/2022 Inside informationwww.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, May 18, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces that the enclosed restructuring proposal (the “Restructuring Proposal”) will be submitted to the Danish Maritime and Commercial High Court (the “Court”) and be sent to the Company’s known creditors foll

  • Globe Newswire

    Updated Financial Calendar for 2022

    Orphazyme A/S in restructuringCompany announcement No. 25/2022www.orphazyme.com Company Registration No. 32266355 Copenhagen, Denmark, May 16, 2022 – Orphazyme A/S in restructuring (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company, announces an update to the Company’s financial calendar for the remainder of 2022 following the signing of a binding agreement with KemPharm, Inc. for sale of substantially all of the company’s assets and business activities durin

  • Globe Newswire

    Orphazyme A/S under In-Court-Restructuring to sell substantially all of its assets and business activities to KemPharm, Inc.

    Orphazyme A/S in restructuringCompany announcementNo. 24/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 KemPharm to acquire Orphazyme assets, including those relating to the development and approval of arimoclomol, for a total of USD 12.8 million in cash and assumed liabilities estimated to equal approximately USD 5.2 millionThe majority of Orphazyme’s approximately 20 current employees will become employees at KemPharmKemPharm intends to continue to pursue approval of